Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Fluorescent Skin Dye Offers Temporary Option for Skin Cancer Management

XTALKS VITALS NEWS

A team of researchers at the University of California, Los Angeles, have developed a novel fluorescent ink to temporarily tag the skin cancer lesion.

Share this!

January 4, 2017 | by Sarah Hand, M.Sc.

With the exception of melanoma, most types are skin cancer lesions are identified and tagged using small tattoos. While this method helps physicians track which areas need additional treatment, the long-lasting tattoo ink used can cause inflammation and can even be confused with lesions when a patient is being monitored in the future.

A team of researchers at the University of California, Los Angeles, have developed a novel fluorescent ink to temporarily tag the skin cancer lesion. Not visible by the naked eye, the dye only fluoresces under light with a wavelength of 465 nanometers.

“Tattooing has been utilized by the medical community for precisely demarcating anatomic landmarks,” said the study authors in their ACS Nano publication. “This practice is especially important for identifying biopsy sites of nonmelanoma skin cancer due to the long interval (i.e., up to 3 months) between the initial diagnostic biopsy and surgical treatment.”



Unlike the standard tattoo dye, the fluorescent ink fades over time. The researchers reported that the retention time of the dye was around 3 months, which coincides with the average time between a patient’s initial biopsy and when they receive surgical treatment.

The transdermal dye is composed of cross-linked fluorescent supramolecular nanoparticles and a fluorescent conjugated polymer center. The fluorescent dye has only been tested in mice, where it showed no propensity to trigger local inflammation.

According to the Canadian Cancer Society, nonmelanoma skin cancer is the most common form of the disease diagnosed in Canada. Statistics on the incidence of these types of skin cancer are, however, difficult to collect because diagnosis and treatment are often both done by a patient’s regular physician.


Keywords: Skin Cancer, Biopsy, Surgery


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.